
Podcast #60 · 17 Nov 2026
Innovations in Coronary Intervention: Drug-Coated Balloons
- Percutaneous Coronary Intervention (PCI)
- In-Stent Restenosis (ISR)
- Interventional Cardiology (IC)
- Drug-Coated Balloon (DCB)
- Drug-Eluting Stent (DES)
- Vessel Preparation
In 1990, Dr. John Lasala watched one of the first coronary stents go into a failing artery and called it “the future of cardiology.” Now he and Dr. Aloke Finn see drug-coated balloons as a possible next shift: treating the artery without leaving a permanent implant behind. On this episode of BackTable Cardiology, Dr. Sameh Sayfo is joined by Dr. Lasala and Dr. Finn to trace coronary intervention from balloon angioplasty to drug-eluting stents, then explain how paclitaxel and sirolimus differ in the arterial wall and what it takes to keep sirolimus in the wall long enough to work. Dr. Lasala, who spent his early research career watching less than 1% of drug reach the vessel wall, admits that 20 years ago he would have called 90 days of drug retention impossible. They also explain why vessel preparation with imaging and specialty balloons must come first.
This podcast is supported by
Timestamps
Resources
- Heldman AW, et al. Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis. Circulation. 2001
- Cutlip DE, et al. Sirolimus-Eluting Balloon vs. Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis (SELUTION4ISR). J Am Coll Cardiol. 2026
- Large De-NOVo Coronary artEry Disease Treated With Sirolimus Drug Eluting Balloon (LOVE DEB). ClinicalTrials.gov NCT05915468
More about this episode
The conversation then turns to technique: contact, inflation time and pressure, why a drug-coated balloon is a drug delivery vehicle rather than a dilation tool, and why one balloon should not be stretched across several segments. Drs. Lasala and Finn compare their approach to three kinds of in-stent restenosis, from old bare metal stents to multiple stent layers, explain how neoatherosclerosis changes the target, and discuss small vessels and shorter dual antiplatelet therapy for patients at high bleeding risk. They close on the randomized data still needed and why uncaging the vessel could become the third revolution in coronary intervention.

